SAGE Sage Therapeutics Inc.

62.84
-0.48  -1%
Previous Close 63.32
Open 63.79
Price To book 9.04
Market Cap 2352797719
Shares 37,441,084
Volume 391,152
Short Ratio 3.59
Av. Daily Volume 611,810

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2017.
Brexanolone - SAGE-547 (202C)
Postpartum Depression - moderate
Phase 2 initiation announced December 19, 2016. Part B data due 2H 2017.
SAGE-217
Major Depressive Disorder (MDD)
Phase 2 initiation announced December 13, 2016. Data from Part A data released May 9, 2017. Part B data due 2H 2017.
SAGE-217
Parkinson’s disease (PD)
Phase 2 initiation 4Q 2016. Data due 2H 2017.
SAGE-217
Postpartum depression (PPD)
Phase 3 data due 2H 2017.
Brexanolone - SAGE-547 (202B)
Postpartum Depression (Severe)
Phase 3 data released September 12, 2017 - primary endpoint not met.
SAGE-547
SRSE
Announced that screening has opened for Phase 2a trial - December 13, 2016. Data due 2H 2017.
SAGE-217
Essential tremor